Jump to main content

yr 〜
yr

Search results 10

Guidance for industry [microform] : content and format of investigational new drug applications (INDs) for phase 1 studies of drugs, including well-characterized, therapeutic, biotechnology-derived products

Guidance for industry [microform] : content and format of investigational new drug applications (INDs) for phase 1 studies of drugs, including well-characterized, therapeutic, biotechnology-derived products
Microform図書
1995<YCA-HE 20.4708:IN 2/2>
National Diet Library

The need for FDA regulatory reform to protect the health and safety of Americans : hearing before the Subcommittee on National Economic Growth, Natural Resources, and Regulatory Affairs of the Committee on Government Reform and Oversight, House of Representatives, One Hundred Fourth Congress, first session, June 9, 1995

The need for FDA regulatory reform to protect the health and safety of Americans : hearing before the Subcommittee on National Economic Growth, Natural Resources, and Regulatory Affairs of the Committee on Government Reform and Oversight, House of Representatives, One Hundred Fourth Congress, first session, June 9, 1995
Microform図書
1996<YCA-Y 4.G 74/7:F 73/19>
National Diet Library

Addressing the FDA's performance, efficiency, and use of resources : hearings of the Committee on Labor and Human Resources, United States Senate, One Hundred Fifth Congress, first session ... March 19 and April 11, 1997 (S. hrg. ; 105-23)

Addressing the FDA's performance, efficiency, and use of resources : hearings of the Committee on Labor and Human Resources, United States Senate, One Hundred Fifth Congress, first session ... March 19 and April 11, 1997 (S. hrg. ; 105-23)
Microform図書
1997<YCA-Y 4.L 11/4:S.HRG.105-23>
National Diet Library

Science, politics, and the pharmaceutical industry : controversy and bias in drug regulation / John Abraham.

Science, politics, and the pharmaceutical industry : controversy and bias in drug regulation / John Abraham.
Paper図書
UCL Press1995.<EG237-A13>
National Diet Library
  • Subject Heading...アメリカ合衆国. イギリス. Drugs -- Testing -- Government policy -- United States. Drugs -- Testing -- Governmen...

New drug approval process : the global challenge 3rd ed.

New drug approval process : the global challenge 3rd ed.
Paper図書
edited by Richard A. GuarinoM. Dekkerc2000
Other Libraries in Japan

New drug approval process : clinical and regulatory management / edited by Richard A. Guarino. (Drugs and the pharmaceutical sciences ; v. 30)

New drug approval process : clinical and regulatory management / edited by Richard A. Guarino. (Drugs and the pharmaceutical sciences ; v. 30)
Paper図書
Dekkerc1987.<SD61-A6>
National Diet Library
  • Subject Heading... -- Standards. Drugs -- Testing -- Government policy -- United States. New products -- Government po...

Science, politics, and the pharmaceutical industry : controversy and bias in drug regulation : hbk : pbk

Science, politics, and the pharmaceutical industry : controversy and bias in drug regulation : hbk : pbk
Paper図書
John AbrahamUCL press1995
Other Libraries in Japan

New drug approval process 2nd ed., rev. & expanded

New drug approval process 2nd ed., rev. & expanded
Paper図書
edited by Richard A. GuarinoM. Dekkerc1993
Other Libraries in Japan

New drug approval process : clinical and regulatory management

New drug approval process : clinical and regulatory management
Paper図書
edited by Richard A. GuarinoDekkerc1987
Other Libraries in Japan

Risk-benefit/cost-benefit : improving government regulation of approval of new drugs

Risk-benefit/cost-benefit : improving government regulation of approval of new drugs
Paper図書
remarks by Rita Ricardo-Campbell, presented at the World Congress on Health and Economics [i.e. World Congress on Health Economics] Leyden University, Leyden, The Netherlands, September 9, 1980Hoover Institution, Stanford University1980
Other Libraries in Japan

Reached to the end of result.

RSS